Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Earnings Results, Beats Estimates By $0.24 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX) posted its earnings results on Monday. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.23 by $0.24, FiscalAI reports. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $2.99 billion.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Vertex reported strong Q1 results with $2.99 billion in product revenue (+8% YoY), reiterated full‑year guidance of $12.95–13.1 billion, ended Q1 with ~$13 billion in cash, and continued share repurchases — supporting near‑term financial momentum.
• Pivotal RAINIER interim Phase III data for povetacicept (Povi) in IgAN were described as “sparkling” — a 52% proteinuria reduction vs baseline (≈49.8% vs placebo), favorable safety, a 27‑day BLA filing turnaround, and initiation/advancement of PMN and gMG programs, underpinning a new renal franchise opportunity.
• Commercial momentum outside CF: CASGEVY has >500 patients initiated and delivered $43M in Q1 while securing reimbursement progress (e.g., Germany), and JOURNAVX surpassed 1M prescriptions written with 350k scripts in Q1 and expanded payer coverage (≈240M lives), supporting the company’s goal of >$500M non‑CF revenue in 2026.
• CF franchise remains core: ALYFTREK exceeded $1 billion cumulative revenue and recent label expansions for ALYFTREK/TRIKAFTA extend eligibility to ~95% of people with CF; next‑gen modulators (VX‑828, VX‑581, VX‑272) are progressing with a VX‑828 patient readout expected H2 2026.
• Vertex discontinued the VX‑522 mRNA program for patients who produce no CFTR protein due to lung inflammatory/tolerability issues, meaning the company will not advance this delivery approach for the hardest‑to‑treat CF patients and must pursue alternative modalities.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX traded up $5.93 during midday trading on Monday, reaching $429.85. The company’s stock had a trading volume of 1,418,049 shares, compared to its average volume of 1,394,366. Vertex Pharmaceuticals has a 12-month low of $362.50 and a 12-month high of $507.92. The firm has a 50 day moving average price of $453.82 and a 200-day moving average price of $449.48. The stock has a market capitalization of $109.34 billion, a P/E ratio of 28.04, a PEG ratio of 1.84 and a beta of 0.30.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Adjusted profit and EPS beat expectations — Vertex reported quarterly EPS that topped Street estimates and strong profitability metrics, supporting near‑term earnings confidence. Vertex Reports First Quarter 2026 Financial Results
• Positive Sentiment: Sales of a new cystic fibrosis drug surged — reports note a near eight‑fold increase in sales of Vertex’s new CF treatment, a key growth driver that helped lift revenue and investor sentiment. Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Positive Sentiment: Regulatory expansion strengthens the CF franchise — FDA expanded use of ALYFTREK for younger CF patients, broadening the addressable market for Vertex’s core cash‑generating franchise. How Investors Are Reacting To Vertex (VRTX) FDA ALYFTREK Expansion and Evolving Pipeline Story
• Positive Sentiment: Underlying profitability and income grew YoY — operating profit and net income showed strong year‑over‑year increases, reinforcing the company’s cash‑flow generation profile. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
• Neutral Sentiment: FY‑2026 revenue guidance reiterated and essentially in line with consensus — management maintained revenue guidance of roughly $13.0–$13.1B, removing some uncertainty but not materially surprising investors. View Press Release
• Neutral Sentiment: Analyst coverage remains broadly positive but targets vary widely — many buy/outperform ratings remain and median targets are well above the current price, suggesting continued long‑term bullishness despite near‑term dispersion. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
• Negative Sentiment: Some third‑party data feeds showed mixed/missed metrics — a published data set reported diluted EPS and revenue below certain consensus figures, which prompted short‑term after‑hours weakness in some quotes. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
• Negative Sentiment: Material insider selling and some institutional reductions — reporting shows significant insider dispositions and large institutional rebalances, which can weigh on near‑term sentiment. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
• Negative Sentiment: Some cash‑flow and balance sheet items need watching — operating cash from activities was reported lower YoY and capex rose, while total liabilities increased, factors investors may monitor for cash conversion and reinvestment. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings

Analyst Upgrades and Downgrades

A number of research firms have issued reports on VRTX. Weiss Ratings downgraded Vertex Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, April 14th. Evercore raised their target price on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Wolfe Research upgraded Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price target for the company in a report on Tuesday, January 6th. HC Wainwright increased their price target on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Finally, Sanford C. Bernstein restated an “outperform” rating and set a $577.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $554.83.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Mark E. Bunnage sold 620 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $301,537.00. Following the completion of the transaction, the executive vice president owned 7,284 shares in the company, valued at $3,542,573.40. This represents a 7.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Carmen Bozic sold 2,329 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $481.79, for a total value of $1,122,088.91. Following the sale, the chief marketing officer directly owned 35,405 shares of the company’s stock, valued at approximately $17,057,774.95. This represents a 6.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 80,431 shares of company stock valued at $37,875,167 in the last ninety days. Insiders own 0.20% of the company’s stock.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in VRTX. Motiv8 Investments LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $26,000. Swiss RE Ltd. bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $28,000. Kelleher Financial Advisors purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $39,000. Triumph Capital Management purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $43,000. Finally, Sfam LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $45,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.